Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®
PR Newswire —
Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma) Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors...